Medical Letter on the CDC & FDA

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Medical Letter on the CDC & FDA


We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Cardiology

Transmyocardial revascularization and gene therapy fight myocardial dysfunction

"The purpose of this study was to investigate whether a novel fibroblast growth factor-2 gene formulation, providing a localized and sustained availability of the adenoviral vector from a collagen-based matrix, in combination with CO₂ transmyocardial laser revascularization would lead to an enhanced angiogenic response and improved myocardial function," investigators in the United States report.

"Fibroblast growth factor-2 gene was delivered by means of an adenoviral vector (adenoviral fibroblast growth factor-2) formulated in a collagen-based matrix," said...

• View Other Issues of Medical Letter on the CDC & FDA
  
• View Other NewsRx Publications